Rapid pain control in Ixekizumab targeted axial spondyloarthritis

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508976-12-00

Acronym

RAPIDA

Enrollment

Registered

2024-01-29

Start date

2024-04-29

Completion date

2025-12-22

Last updated

2024-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

axial spondyloarthritis

Brief summary

Change in fMRI BOLD signal voxel count during initial treatment with Ixekizumab (day 17 vs. day 14) as compared to change in fMRI BOLD signal voxel count during pre-treatment (day 3 vs. day 0)

Interventions

DRUGTaltz 80 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in fMRI BOLD signal voxel count during initial treatment with Ixekizumab (day 17 vs. day 14) as compared to change in fMRI BOLD signal voxel count during pre-treatment (day 3 vs. day 0)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026